The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Open accessAbstract
Background —Elevated plasma concentrations of C-reactive protein (CRP) are associated with increased cardiovascular risk. We evaluated whether long-term therapy with pravastatin, an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter. Methods and Results —CRP levels were measured at baseline and at 5 years in 472 randomly selected participants in the Cholesterol and Recurrent Events (CARE) trial who remained free of recurrent coronary events during follow-up. Overall, CRP levels at baseline and at 5 years were highly correlated ( r =0.60, P <0.001). However, among those allocated to placebo, median CRP levels and the mean change in CRP tended to increase over time (median change, +4.2%; P =0.2 and mean change, +0.07 mg/dL; P =0.04). By contrast, median CRP levels and the mean change in CRP decreased over time among those allocated to pravastatin (median change, −17.4%; P =0.004 and mean change, −0.07 mg/dL; P =0.002). Thus, statistically significant differences were observed at 5 years between the pravastatin and placebo groups in terms of median CRP levels (difference, −21.6%; P =0.007), mean CRP levels (difference, −37.8%; P =0.002), and absolute mean change in CRP (difference, −0.137 mg/dL; P =0.003). These effects persisted in analyses stratified by age, body mass index, smoking status, blood pressure, and baseline lipid levels. Attempts to relate the magnitude of change in CRP to the magnitude of change in lipids in both the pravastatin and placebo groups did not reveal any obvious relationships. Conclusions —Among survivors of myocardial infarction on standard therapy plus placebo, CRP levels tended to increase over 5 years of follow-up. In contrast, randomization to pravastatin resulted in significant reductions in this inflammatory marker that were not related to the magnitude of lipid alterations observed. Thus, these data further support the potential for nonlipid effects of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642
Self-citationProduction of C-reactive protein and risk of coronary events in stable and unstable angina
Haverkate, E., Thompson, S. G., Pyke, S. D., Gallimore, J. R., & Group, M. B. P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07591-5 · Cited by 1,500
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Self-citationRelation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control Study
for the MRFIT Research Group, Kuller, L. H., Tracy, R. P., Shaten, J., & Meilahn, E. N. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008963 · Cited by 1,097
Ridker, P. M., Glynn, R. J., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.20.2007 · Cited by 1,013
Self-citationAntiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Tracy, R. P., Lemaitre, R. N., Psaty, B. M., Ives, D. G., Evans, R. W., Cushman, M., Meilahn, E. N., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1121 · Cited by 836
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 796
Aikawa, M., Rabkin, E., Okada, Y., Voglic, S. J., Clinton, S. K., Brinckerhoff, C. E., Sukhova, G. K., & Libby, P. (1998) · Circulation · doi:10.1161/01.cir.97.24.2433 · Cited by 555
HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages
Bellosta, S., Via, D., Canavesi, M., Pfister, P., Fumagalli, R., Paoletti, R., & Bernini, F. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.11.1671 · Cited by 512
Williams, J. K., Sukhova, G. K., Herrington, D. M., & Libby, P. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00537-8 · Cited by 348
Ledue, T. B., Weiner, D. L., Sipe, J. D., Poulin, S. E., Collins, M. F., & Rifai, N. (1998) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329803500607 · Cited by 321
Self-citationEffect of statins on C-reactive protein in patients with coronary artery disease
Strandberg, T. E., Vanhanen, H., & Tikkanen, M. J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)76154-7 · Cited by 209
Shiomi, M., Ito, T., Tsukada, T., Yata, T., Watanabe, Y., Tsujita, Y., Fukami, M., Fukushige, J.-I., Hosokawa, T., & Tamura, A. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1938 · Cited by 128
Sacks, F. M., Pfeffer, M. A., Moyé, L. A., Brown, L. E., Hamm, P., Cole, T. G., HAWKINS, C. M., Braunwald, E., & The CARE Investigators (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90276-q · Cited by 125
Self-citationProspective Studies of C-Reactive Protein as a Risk Factor for Cardiovascular Disease
Ridker, P. M., & Haughie, P. (1998) · Journal of Investigative Medicine · doi:10.1177/170882679804600814 · Cited by 114
Self-citationKeidar, S., Aviram, M., Maor, I., Oiknine, J., & Brook, J. G. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04392.x · Cited by 82
Cited by
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Self-citationBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationRidker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citationC-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Metadata
- Authors
- Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E.
- Venue
- Circulation
- Published
- 1999-07-20
- Volume
- 100
- Issue
- 3
- Pages
- 230-235
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2145053304
- Cited by
- 1,478
- References
- 25
- FWCI
- 114.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.